Dishman Carbogen AmicsNSE:DCAL -3.22%70 Return-on-Tangible-Equity is 5.88% as of Mar. 2026, which is 56% above its 10-year median of 3.77. GuruFocus rates NSE:DCAL with a GF Score™ of 70/100 and a GF Value™ of ₹237.42 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,196 Biotechnology companies, Dishman Carbogen Amics ranks better than 83.53% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Dishman Carbogen Amics's annualized net income for the quarter that ended in Mar. 2026 was ₹870 Mil. Dishman Carbogen Amics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹14,788 Mil. Therefore, Dishman Carbogen Amics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.88%.
The historical rank and industry rank for Dishman Carbogen Amics's Return-on-Tangible-Equity or its related term are showing as below:
NSE:DCAL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.29 Med: 3.77 Max: 12.72
Current: 6.56
During the past 13 years, Dishman Carbogen Amics's highest Return-on-Tangible-Equity was 12.72%. The lowest was -9.29%. And the median was 3.77%.
NSE:DCAL's Return-on-Tangible-Equity is ranked better than 83.53% of 1196
companies
in the Biotechnology industry
Industry Median: -42.19
vs NSE:DCAL: 6.56
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Dishman Carbogen Amics Return-on-Tangible-Equity Related Terms
Dishman Carbogen Amics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Dishman Carbogen Amics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:DCAL vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Dishman Carbogen Amics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dishman Carbogen Amics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Dishman Carbogen Amics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.88% mean?
Dishman Carbogen Amics (NSE:DCAL) has a Return-on-Tangible-Equity of 5.88% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dishman Carbogen Amics and its competitors. This is 56% above median its historical median of 3.77. According to the industry distribution chart, Dishman Carbogen Amics ranks #197 out of 1196 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Dishman Carbogen Amics' Return-on-Tangible-Equity too high?
Dishman Carbogen Amics' current Return-on-Tangible-Equity of 5.88% is 56% above median its 10-year median of 3.77. Based on the distribution chart, Dishman Carbogen Amics ranks #197 out of 1196 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dishman Carbogen Amics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dishman Carbogen Amics' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dishman Carbogen Amics ranks #197 out of 1196 companies for Return-on-Tangible-Equity. This places Dishman Carbogen Amics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dishman Carbogen Amics and its competitors. Dishman Carbogen Amics's current Return-on-Tangible-Equity is 5.88%, which is 56% above median its own 10-year median of 3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dishman Carbogen Amics stock overvalued right now?
Based on GuruFocus' analysis, Dishman Carbogen Amics (NSE:DCAL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹237.42, compared to a current price of ₹191.27 — trading 19.4% below its estimated fair value. The current Return-on-Tangible-Equity is 5.88%, which is 56% above median its 10-year median of 3.77. Dishman Carbogen Amics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Dishman Carbogen Amics (NSE:DCAL), the current Return-on-Tangible-Equity is 5.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?
Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued.
The current stock price of ₹191.27 is trading 19.4% below its estimated GF Value™ of ₹237.42.
GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.
Key valuation signals for NSE:DCAL:
Return-on-Tangible-Equity: 5.88% (56% above median its 10-year median of 3.77)
GF Value™: ₹237.42 vs. price of ₹191.27 (19.4% below fair value)
No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
70GF Score
Get the complete analysis for NSE:DCAL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:DCAL has been successfully added to your 
